Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 5/20 | 0.58 |
| ▸ | TOP2A | P11388 | 3/20 | 0.58 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.58 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.50 |
| ▸ | PARP14 | Q460N5 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3742777 | 0.89 | TOP1 (0.59) | TOP1TOP2ATOP2BP2RY1PARP14 | |
| SCHEMBL11724397 | 0.87 | PARP14 (0.55) | P2RY1PARP14LMNACHEK1KDR | |
| SCHEMBL3737843 | 0.86 | P2RY1 (0.51) | P2RY1PARP14GAALMNACHEK1 | |
| SCHEMBL3743012 | 0.84 | LMNA (0.54) | P2RY1GAAKDM4EMEN1ALDH1A1 | |
| SCHEMBL23729917 | 0.82 | P2RY1 (0.50) | P2RY1PARP14MEN1KMT2ATDP1 | |
| SCHEMBL2740083 | 0.80 | SMO (0.58) | P2RY1GAAKDM4EMEN1ALDH1A1 | |
| Pyrimidine SCHEMBL3397113 | 0.80 | ITK (0.52) | P2RY1PARP14HPGDLMNAPOLB | |
| SCHEMBL11726409 | 0.79 | P2RY1 (0.56) | P2RY1PARP14GAAKDM4EMEN1 | |
| SCHEMBL4352826 | 0.79 | TOP1 (0.55) | TOP1TOP2ATOP2BGAAKDM4E | |
| SCHEMBL3538594 | 0.79 | P2RY1 (0.51) | P2RY1ALDH1A1KMT2ALMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2039683-B1 | Vasculostatic agents and methods of use thereof | TARGEGEN INC (US) | 2012-12-19 | — | — | EP | disclosed |
| EP-2039683-B1 | Vasculostatic agents and methods of use thereof | TARGEGEN INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC. | 2010-11-04 | — | — | US | disclosed |
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC. | 2010-11-04 | — | — | US | disclosed |
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC. | 2010-11-04 | — | — | US | disclosed |
| EP-2039683-A2 | Vasculostatic agents and methods of use thereof | Targegen, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-1549614-A4 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20070208019-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208019-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. | 2007-09-06 | — | — | US | disclosed |
| US-7208493-B2 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208493-B2 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208493-B2 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| CN-1720224-A | Vascular balancing agents and methods of use thereof | TARGEGEN INC (US) | 2006-01-11 | — | — | CN | disclosed |
| US-20050282814-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| EP-1549614-A2 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | Targegen, Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040167198-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. | 2004-08-26 | — | — | US | disclosed |
| WO-2004030635-A2 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN, INC. (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | RBP1, RBP4, VCAM1 | TOP1 2523/4885TOP2A 2995/4885TOP2B 3335/4885 |
| US-20050282814-A1 | Vasculostatic agents and methods of use thereof | RBP1, RBP4, VCAM1 | TOP1 2523/4885TOP2A 2995/4885TOP2B 3335/4885 |
| US-20070208019-A1 | Vasculostatic agents and methods of use thereof | RBP1, RBP4, VCAM1 | TOP1 2523/4885TOP2A 2995/4885TOP2B 3335/4885 |
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | RBP1, RBP4, VCAM1 | TOP1 2523/4885TOP2A 2995/4885TOP2B 3335/4885 |
| US-20040167198-A1 | Vasculostatic agents and methods of use thereof | RBP1, RBP4, VCAM1 | TOP1 2523/4885TOP2A 2995/4885TOP2B 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.